Enlivex opened lower at $1.25, compared with its previous close of $1.26. In the last trading session, the stock traded between $1.19 and $1.34. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Enlivex is now worth
$ 1.01
Resulting in a loss of
$ 98.99 (98.99%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.03 (-2.38%)
Day High
$1.34
Day Low
$1.19
Day Open
$1.25
Prev Close
$1.26
Volume
20,276
1W Return
-11.26%
1M Return
388.10%
3M Return
-36.43%
6M Return
-88.97%
1Y Return
-92.12%
Fundamentals
Market Cap ($ Mn)
2
PE Ratio
0.00
PB Ratio
0.01
PEG Ratio
-
ROE
306.48%
ROCE
336.96%
EPS (TTM)
$1,798.11
Investment Returns
1 Week
-11.26%
1 Month
388.10%
3 Months
-36.43%
6 Months
-88.97%
9 Months
-92.81%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
19Oct
Enlivex cuts workforce 60% to prioritize Phase 2b knee OA trial
Enlivex reduces workforce by 60% and cuts CEO salary by 40%. Non-clinical R&D activities wound down immediately to save cash. Phase 2b trial data for Allocetra expected by mid-2027. Trial targets patients aged 64+ with moderate-to-severe knee OA.
24 days ago
30Jul
Enlivex Rain protocol trading volume hits $860 million
Enlivex Ltd announced that Rain protocol trading volume reached $860 million in July 2026, up 622% from June. The company projects volumes to grow to $33 billion by 2029, with corresponding increases in fees allocated for RAIN token buy-and-burn mechanisms.
3mo ago
28Jul
Enlivex secures $400M private placement with single investor
Enlivex Therapeutics announces a $400M private placement with a single institutional investor, priced at $5.00 or $6.00 per share depending on whether funding is via fiat/stablecoins or RAIN tokens. The deal includes an option for an additional $400M over 36 months. Proceeds will fund the company's treasury strategy around the Rain protocol and advance its Allocetra™ immunotherapy for age-related osteoarthritis.
3mo ago
20Jul
Enlivex reports NAV of $66.16 per share
Enlivex Ltd. disclosed a net asset value of $66.16 per ordinary share and total RAIN token holdings valued at approximately $1.1 billion as of July 18, 2026. The unaudited mark-to-market metrics are accessible via the company's dashboard.
3mo ago
22Jun
Enlivex holds 79.569B RAIN token with total value of ~$1.14B
Enlivex Ltd. disclosed that its treasury holdings of 79,568,550,005 RAIN tokens were valued at approximately $1.14 billion as of June 20, 2026, resulting in a Treasury NAV per Share of $4.67.
4mo ago
15Jun
Enlivex secures Australian patent for osteoarthritis treatment
Enlivex has secured an Australian patent for Allocetra™, providing protection through 2040 for treating osteoarthritis. The patent strengthens the company's global IP position as its Phase 2b clinical trial advances, with the first patient dosed at a U.S. site. The trial follows positive topline data from earlier stages of the ENX-CL-05-001 study.
